Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention

Background High on-treatment platelet reactivity (HTPR) after clopidogrel is associated with a higher risk of cardiovascular events after percutaneous coronary intervention (PCI). However, it remains unclear whether HTPR is of similar prognostic value for different clinical presentations. Methods We...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American heart journal 2013, Vol.165 (1), p.34-42.e1
Hauptverfasser:	Park, Duk-Woo, MD, Ahn, Jung-Min, MD, Song, Hae-Geun, MD, Lee, Jong-Young, MD, Kim, Won-Jang, MD, Kang, Soo-Jin, MD, Yun, Sung-Cheol, PhD, Lee, Seung-Whan, MD, Kim, Young-Hak, MD, Lee, Cheol Whan, MD, Park, Seong-Wook, MD, Park, Seung-Jung, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Coronary Syndrome - drug therapy Acute Coronary Syndrome - mortality Acute Coronary Syndrome - surgery Acute coronary syndromes Aged Blood platelets Cardiovascular Cardiovascular disease Clinical outcomes Coronary Artery Disease - drug therapy Coronary Artery Disease - mortality Coronary Artery Disease - surgery Coronary vessels Female Follow-Up Studies Heart attacks Hemorrhage - chemically induced Humans Male Middle Aged Percutaneous Coronary Intervention - methods Percutaneous Coronary Intervention - mortality Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Platelet Function Tests Prognosis Statistical methods Stroke Stroke - chemically induced Studies Thrombosis Thrombosis - chemically induced Ticlopidine - adverse effects Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background High on-treatment platelet reactivity (HTPR) after clopidogrel is associated with a higher risk of cardiovascular events after percutaneous coronary intervention (PCI). However, it remains unclear whether HTPR is of similar prognostic value for different clinical presentations. Methods We compared the prognostic impact of HTPR, measured by the VerifyNow P2Y12 assay (Accumetrics, San Diego, CA), on outcomes between 1,095 patients with acute coronary syndromes (ACS) and 1,329 patients with stable coronary artery disease (CAD) who were treated with PCI. Before PCI, patients received optimal clopidogrel treatment (75 mg daily for at least 5 days or if
ISSN:	0002-8703 1097-6744
DOI:	10.1016/j.ahj.2012.10.013